As we pass the midpoint of 2026, MABWELL-B (02493) is positioned at the starting line of a new round of value reassessment. With the release of multiple significant clinical datasets for its core asset, 9MW2821, the commercialization process for this product is accelerating. Concurrently, the company's commercialized product, Maiweijian® (Denosumab Injection), recently received approval for a supplemental application for new indications covering solid tumor bone metastases and multiple myeloma, indicating a broadening revenue stream from its marketed portfolio. At a time when investment logic in the innovative drug sector increasingly prioritizes commercial execution, the clear commercialization timeline for core products over the next year, combined with the ongoing performance contribution from existing products, positions MABWELL-B for a potential event-driven window of value reassessment.
Core Asset Shows Strong Clinical Data
9MW2821 is a Nectin-4 targeted ADC innovative drug independently developed by MABWELL-B and is the world's first Nectin-4 ADC to enter Phase III clinical trials for cervical cancer (CC) and triple-negative breast cancer (TNBC) indications. Recently, multiple clinical study data presented by the company at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated excellent efficacy. In the Ib/II phase clinical study combining it with Toripalimab (PD-1) for locally advanced or metastatic urothelial carcinoma (la/mUC), the overall population objective response rate (ORR) was 83.0%, the confirmed ORR was 74.5%, the complete response (CR) rate was 12.8%, and the median progression-free survival (PFS) was 12.9 months. Previous research data showed, in a non-head-to-head comparison, that Padcev combined with Keytruda in a Phase 3 study for UC had a cORR of 67.5%, mPFS of 12.5 months, and mOS of 33.8 months. The experimental results indicate that the combination of 9MW2821 and PD-1 Toripalimab in the first-line UC 1b/2 phase study showed efficacy data superior to the Padcev-Keytruda combination, highlighting its potential "Best-in-class" attributes.
Furthermore, in a Phase II clinical study of the combination with PD-1 for perioperative muscle-invasive bladder cancer (MIBC), one subject achieved a clinical complete response (CR), with a pathological complete response rate (pCR) of 66.7% (4/6) and a pathological downstaging (pDS) rate of 83.3% (5/6). Given the high expression of Nectin4 in several solid tumors including TNBC and CC, these results further strengthen the expectation that 9MW2821 could become a broad-spectrum anti-tumor blockbuster in the future.
To date, 9MW2821 has initiated four Phase III pivotal registration clinical trials, with three indications receiving FDA Fast Track designation, one receiving Orphan Drug designation, and two indications included in the NMPA CDE's Breakthrough Therapy Designation list. Interim analyses for the Phase III clinical trials of the UC monotherapy, combination therapy, and CC monotherapy are planned for 2026, with the potential to submit pre-NDA meeting applications to the NMPA CDE based on the interim analysis data.
Regarding market competition, the global Nectin-4 targeted ADC landscape currently has only one marketed product—Padcev, developed by Astellas in collaboration with Pfizer—which achieved global sales of $2.306 billion (approximately RMB 15.8 billion) in 2025, indicating a vast market potential. According to Frost & Sullivan data, among all Nectin-4 ADCs under development in China for treating UC, 9MW2821 is the most advanced, trailing only Padcev globally. Additionally, 9MW2821 is the world's first Nectin-4 ADC to enter pivotal Phase III trials for CC and TNBC, positioning it to potentially capture this differentiated blue ocean market with a first-mover advantage.
It is noteworthy that "PD-1 + ADC" combination therapies, which can achieve high complementarity in their mechanisms of action, have become a highly promising direction in cancer therapy research. Merck's previous research showed that Padcev (enfortumab vedotin) combined with the PD-1 inhibitor pembrolizumab (Keytruda) in the neoadjuvant/adjuvant treatment of MIBC significantly reduced the risk of disease recurrence or death by 60%, with a pCR as high as 57.1%, making it the world's first approved "PD-1+ADC" combination therapy. The combination of 9MW2821 and Toripalimab has similarly demonstrated excellent efficacy in clinical trials, undoubtedly validating the potential of this combination approach once more.
Dual "ADC+TCE" Platform Leads, Multi-Tiered Pipeline Lays Long-Term Foundation
Looking at MABWELL-B's overall pipeline, four marketed drugs are providing a steady stream of cash flow, offering ample funding for subsequent R&D. Public data shows the company currently has four marketed drugs: Mailishu® (orthopedics), Maiweijian® (oncology), Mailisheng® (febrile neutropenia), and Junmaikang®. Among these, Maiweijian is China's first approved biosimilar of denosumab (120mg) for treating giant cell tumor of bone (GCTB); currently, there are only five marketed drugs in China for GCTB treatment. This product recently gained approval for new indications covering solid tumor bone metastases and multiple myeloma. Bone metastases are a typical concomitant condition in the late stages of several high-incidence solid tumors. Public research indicates the probability of bone metastasis exceeds 80% in prostate cancer, about 70% in advanced breast cancer, and reaches 40% in both lung and kidney cancers.
According to the latest disclosures, Maiweijian has submitted marketing applications in eight countries including Jordan, Egypt, and Brazil, and has signed formal cooperation agreements with 33 countries including Saudi Arabia, Singapore, and Malaysia. With overseas market expansion and new indication approvals, this product is expected to achieve rapid commercial scale-up in the future.
In June 2025, MABWELL-B and its subsidiary Taikang Biotech entered into a collaboration with Qilu Pharmaceutical for Mailisheng®, for which Taikang Biotech will receive up to RMB 500 million in upfront and sales milestone payments, plus royalties of up to a double-digit percentage of net sales. Qilu Pharmaceutical itself possesses several marketed innovative oncology drugs and mature commercial resources; this collaboration is expected to contribute stable cash flow returns over an extended period.
The mid-term R&D pipeline focuses on two cutting-edge areas: ADC and TCE. Leveraging strong R&D capabilities from multiple core technology platforms, the company continues to produce several innovative drug candidates, further strengthening its differentiated competitive barriers. In the ADC field, the company has built a next-generation ADC drug development platform and an ADC site-specific conjugation technology platform through four core technologies (DARfinity site-specific conjugation, IDconnect linker, Mtoxin novel payload, LysOnly linker structure). The developed ADC candidates exhibit better structural homogeneity, quality stability, efficacy, and tolerability. Targeting different tumor-associated antigens, MABWELL-B has a diversified ADC portfolio, such as 7MW3711 targeting B7-H3 and 7MW4911 specifically targeting CDH17. Both have initiated Phase I/II clinical trials for monotherapy in advanced solid tumors. 7MW3711 has received FDA Orphan Drug designation for treating small cell lung cancer, while 7MW4911 has shown potent anti-tumor activity in various gastrointestinal tumor CDX/PDX models.
In the TCE field, the company has developed a bi/tri-specific antibody platform capable of simultaneously and specifically binding tumor-associated antigens and the T cell CD3 epitope, precisely targeting tumor antigens with different expression levels while replacing cytotoxic drugs; it also allows for differentiated antibody development based on the unique structural and functional requirements of each candidate, significantly accelerating the antibody R&D and production process from preclinical studies to commercial-scale manufacturing. Among these, 6MW5311 is the world's first TCE innovative drug targeting LILRB4/CD3 to enter clinical declaration, with its IND application accepted by the NMPA and its US clinical trial application currently in the pre-IND stage. With a unique structural design, 6MW5311 exhibits extremely low binding activity to T cells in a tumor-free environment but shows potent tumor cell-killing effects in the tumor-T cell co-existing microenvironment, significantly improving safety while ensuring efficacy.
It is worth special attention that beyond ADC and TCE, the company has also positioned several differentiated candidates with substantial market potential. For example, 9MW1911 is an anti-ST2 monoclonal antibody targeting chronic obstructive pulmonary disease (COPD). COPD is the world's third leading cause of death, affecting over 300 million patients. Current standard treatments primarily alleviate symptoms, yet over 50% of patients still experience acute exacerbations, indicating unmet clinical needs. This drug is planned to enter Phase III clinical trials for COPD in the second half of 2026. If successful, it could become China's first approved anti-ST2 monoclonal antibody, with considerable commercial prospects.
For autoimmune diseases, the company's self-developed innovative antibody, 9MW5211, can precisely intervene in the abnormal activation and tissue infiltration of immune cells. Recently, the US IND application for this drug's injection for inflammatory bowel disease (IBD) was permitted by the FDA, and domestic clinical trials have also been approved. Clinical trial applications for multiple indications including multiple sclerosis (MS) have been accepted by the NMPA.
Additionally, the α-synuclein (α-syn) PET tracer 18F-FD4 (SST001), independently developed by Sinosai Biotech, a company invested in and incubated by MABWELL-B, was recently approved by the NMPA to initiate Phase I clinical trials. This tracer is expected to provide more objective, quantifiable imaging evidence for the early diagnosis and disease subtyping of Parkinson's disease and other α-synucleinopathies. It is the first self-developed α-syn PET tracer in China to enter the registered clinical research stage.
It is evident that MABWELL-B has formed a clearly tiered R&D pipeline portfolio: marketed products continue to expand into new indications; multiple promising candidates in the ADC and TCE fields support mid-term growth; and differentiated candidates in non-oncology, autoimmune, and diagnostic areas provide long-term potential.
Summary and Outlook
Overall, in the short term, MABWELL-B's core assets are set to witness multiple clinical advancements within the next year. Interim analyses for three Phase III trials of 9MW2821 are planned for 2026, with pre-IND meetings to be submitted based on the data, and numerous positive events are expected to serve as direct catalysts for valuation uplift. From a medium to long-term perspective, the multi-layered R&D pipeline matrix gives the company significantly greater long-term certainty compared to innovative drug firms driven by a single pipeline. This, combined with the self-sustaining capability brought by the ongoing scale-up of marketed products, appears particularly valuable in the current environment where the innovative drug sector places greater emphasis on commercial monetization. Catalyzed by multiple factors, it is predictable that MABWELL-B is entering an upward trajectory where performance and valuation are poised to resonate continuously.
Comments